drugset
drugset / Trial / NCT06462183

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

NCT06462183 ↗

Phase 1 Recruiting 105 enrolled Rgenta Therapeutics Inc
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC

Timeline

Start
2024-08-19
Primary completion
2025-12
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject RGT-61159 Small molecule — Oral

Indications

adenoid cystic carcinoma colorectal cancer